Valuation: Fusion Antibodies plc

Market Cap 15.02M 19.94M 17.56M 16.64M 28.31M 1.91B 28.67M 199M 76.6M 977M 74.87M 73.24M 3.13B P/E 2027 *
-13.3x
P/E 2028 * -
Enterprise Value 15.02M 19.94M 17.56M 16.64M 28.31M 1.91B 28.67M 199M 76.6M 977M 74.87M 73.24M 3.13B EV / Sales 2027 *
7.15x
EV / Sales 2028 * -
Free-Float
87.63%
Yield 2027 *
-
Yield 2028 * -
1 day-4.17%
1 week+2.68%
Current month-8.00%
1 month-6.12%
3 months+4.55%
6 months-10.85%
Current year-17.86%
1 week 11
Extreme 11
13
1 month 9
Extreme 9
13.5
Current year 9
Extreme 9
17
1 year 9
Extreme 9
20
3 years 2.8
Extreme 2.8
21
5 years 2.8
Extreme 2.8
135
10 years 2.8
Extreme 2.8
250
Manager TitleAgeSince
Chief Executive Officer 59 2022-08-14
Director of Finance/CFO 52 2023-08-23
Chief Operating Officer - 2023-09-30
Director TitleAgeSince
Chairman 68 2011-08-31
Director/Board Member 50 2011-08-31
Director/Board Member 71 2006-12-31
Date Insider Type Main position Quantity % Market Cap. Importance
2/17/26 Others

Chairman

200,000 0.1760%
1/27/26 Free

Chief Technology Officer

125,282 0.1102%
1/27/26 Free

Chief Executive Officer

183,438 0.1614%
Change 5-day change 1-year change 3-year change Capi.($)
-4.17%+2.68%-34.29%+104.44% 19.83M
+4.16%-0.30%+58.96%+94.17% 71.53B
-0.19%+1.32%+37.20%+81.33% 60.12B
-1.51%+2.39%+9.10%+36.79% 48.85B
+0.46%+1.13%+42.61%+39.71% 44.28B
+0.82%+8.55%+343.37%+691.19% 43.83B
+1.21%+1.43%+8.66%+107.40% 41.53B
-0.67%-0.45%+4.47%+46.37% 30.13B
+4.77%+6.46%+41.54%+22.78% 27.98B
-0.29%-2.17%-19.61%+356.33% 25.25B
Average +0.49%+1.14%+49.20%+158.05% 39.35B
Weighted average by Cap. +1.12%+0.63%+63.52%+154.93%

Financials

2027 *2028 *
Net sales 2.1M 2.79M 2.46M 2.33M 3.96M 267M 4.01M 27.83M 10.71M 137M 10.47M 10.24M 438M -
Net income -1.19M -1.57M -1.39M -1.31M -2.24M -151M -2.26M -15.72M -6.05M -77.18M -5.91M -5.78M -247M -
Net Debt - -
Logo Fusion Antibodies plc
Fusion Antibodies plc is a United Kingdom-based collaborative research organization (CRO) company. The Company offers an integrated end-to-end range of antibody discovery, engineering and expression services for all stages of human therapeutic, veterinary therapeutic and diagnostic antibody development. It offers a range of services including antibody discovery/generation, development, characterization, optimization, and small-scale production. In addition, the Company also offers antigen design, antigen expression, antibody purification and sequencing, antibody humanization using Fusion's proprietary CDRx platform and cell line development, producing antibody generating stable cell lines optimized for downstream use by the customer to produce material for clinical trials. Its Integrated Therapeutic Antibody Services (ITA) offering enhances the efficiency of this process by providing a continuous service offering from as early as target nomination to as far as a stable cell line.
Employees
27
Date Price Change Volume
26-09-30 GBX 11.50 -4.17% 287,051
26-09-29 GBX 12.00 -4.00% 173,668
26-09-28 GBX 12.50 +6.38% 548,988
26-09-25 GBX 11.75 -2.08% 563,911
26-09-24 GBX 12.00 +7.14% 473,349

Quarterly revenue - Rate of surprise